Test Code: 6347

Ataxia with Oculomotor Apraxia Type 2: SETX Gene Sequencing
Test Code: 6347
Turnaround time: 7 weeks

CONDITION DESCRIPTION
Mutations in the SETX gene (9q34) are associated with three different conditions: ataxia with oculomotor apraxia type 2 (AOA2), juvenile amyotrophic lateral sclerosis (ALS4) and autosomal dominant ataxia.

AOA2 is characterized by cerebellar ataxia, axonal sensoimotor neuropathy, oculomotor apraxia , and elevated serum concentration of alpha- fetoprotein. Other characteristics include marked cerebellar atrophy on MRI and signs of axonal neuropathy on EMG. The age of onset is between ages three and 30 years. There is a slow progression of the phenotype. Cardiac involvement, cancer predisposition, and immunodeficiency are usually absent. Ataxia is often the first sign of AOA2 and causes the majority of disability early in the disease progression. Later in the disease course, peripheral sensorimotor neuropathy, especially in the lower limbs, causes the majority of disease progression.

Both sequence alterations and partial or whole gene deletions and duplications of the SETX gene have been reported. AOA2 is inherited in an autosomal recessive manner. Carriers are asymptomatic.

ALS4 is associated with three different autosomal dominant missense mutations in the SETX gene:T3I, L389S, R2136H. It is characterized by severe distal muscle weakness and atrophy and signs associated with degeneration of motor neurons in the central nervous system. Individuals with ALS4 have normal sensation, onset before the age of 25, slow disease progression, and a normal life span.

Two mutations in cis in the SETX gene have been identified in a family with an autosomal dominant form of ataxia. Affected individuals in this family had cerebellar ataxia with atrophy of the cerebellum, dysarthria, oculomotor defects, and tremor. Mental status, reflexes, sensation, muscle tone, and levels of alpha-fetoprotein were in the normal range.

References:
GeneReviews

GENES
SETX

INDICATIONS
This test is indicated for:

  • Confirmation of a clinical diagnosis of AOA2.
  • Carrier testing in adults with a family history of AOA2.

METHODOLOGY

Next Generation Sequencing: In-solution hybridization of all coding exons is performed on the patient’s genomic DNA. Although some deep intronic regions may also be analyzed, this assay is not mean to interrogate most promoter regions, deep intronic regions, or other regulatory elements, and does not detect single or multi-exon deletions or duplications. Direct sequencing of the captured regions is performed using next generation sequencing. The patient’s gene sequences are then compared to a standard reference sequence. Potentially causative variants and areas of low coverage are Sanger-sequenced. Sequence variations are classified as pathogenic, likely pathogenic, benign, likely benign, or variants of unknown significance. Variants of unknown significance may require further studies of the patient and/or family members.

DETECTION
Clinical Sensitivity: Unknown. Mutations in the promoter region, some mutations in the introns and other regulatory element mutations cannot be detected by this analysis. Large deletions will not be detected by this analysis. Results of molecular analysis should be interpreted in the context of the patient’s clinical and/or biochemical phenotype.

Analytical Sensitivity: ~99%

SPECIMEN REQUIREMENTS
Submit only 1 of the following specimen types
* Preferred specimen type: Whole Blood

Type: Whole Blood
Specimen Requirements:
In EDTA (purple top) or ACD (yellow top) tube: Infants (2 years): 3-5 ml
Older Children & Adults: 5-10 ml

Specimen Collection and Shipping: Refrigerate until time of shipment. Ship sample within 5 days of collection at room temperature with overnight delivery.

Type: Saliva
Specimen Requirements:

OrageneTM Saliva Collection kit (available through CEN4GEN) used according to manufacturer instructions.
Specimen Collection and Shipping: Store sample at room temperature. Ship sample within 5 days of collection at room temperature with overnight delivery.

RELATED TESTS

  • Custom diagnostic mutation analysis (test code: 6875) is available to family members if mutations are identified by targeted mutation testing or sequencing analysis.